The Cytel Blog: Perspectives on Enquiry & Evidence

The world's leading supplier of statistical insight to decision-makers in the lifesciences brings you debate and discussion of the newest trends in statistics and quantitative strategy.

December 5, 2019

Biotechs and Medtechs, don’t forget your market access strategy (part 4 of 4): How to optimize your market access planning approach

Author: Michael S. Paas, Market Access & Commercialization Expert, Executive at AbbVie and Guest Author at Cytel In..

Read article

December 2, 2019

Biotechs and Medtechs, don’t forget your market access strategy (part 3 of 4): Harnessing the value of market access planning

Author: Michael S. Paas, Market Access & Commercialization Expert, Executive at AbbVie and Guest Author at Cytel..

Read article

November 21, 2019

Biotechs and Medtechs, don’t forget your market access strategy (part 2 of 4): The critical role of market access planning in clinical development

Author: Michael S. Paas, Market Access & Commercialization Expert, Executive at AbbVie and Guest Author at Cytel In my..

Read article

November 14, 2019

Biotechs and Medtechs, don’t forget your market access strategy (part 1of 4): Why is market access strategy crucial to succeed?

Market access strategy is an integral part of the clinical development process to ensure success in global healthcare..

Read article

|All posts|

The Cytel Blog: Perspectives on Enquiry & Evidence

Biotechs and Medtechs, don’t forget your market access strategy (part 4 of 4): How to optimize your market access planning approach

Biotechs and Medtechs, don’t forget your market access strategy (part 3 of 4): Harnessing the value of market access planning

Biotechs and Medtechs, don’t forget your market access strategy (part 2 of 4): The critical role of market access planning in clinical development

Biotechs and Medtechs, don’t forget your market access strategy (part 1of 4): Why is market access strategy crucial to succeed?

Subscribe to our weekly newsletter